Syndax Pharmaceuticals, Inc.
syndax.comWhat Do They Do?
Sells Revuforj, a medicine for certain acute leukemias, and develops cancer therapies for patients with blood cancers and related diseases.
10-K for FY2025, filed Feb 26, 2026We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved…View ↗
Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the…View ↗
Niktimvo is our first-in-class colony stimulating factor-1 receptor, or CSF-1R, blocking antibody that was approved by the FDA in August…View ↗
We licensed the global rights to revumenib and axatilimab, the first two FDA approved medicines to emerge from our pipeline. We are leading…View ↗
How Do They Make Money?
Specialty distributors and specialty pharmacies pay for Revuforj when it is delivered. Syndax also receives its share of Niktimvo sales through its collaboration with Incyte, and license and milestone payments under agreements with partners.
10-K for FY2025, filed Feb 26, 2026The Company sells Revuforj to specialty distributors and specialty pharmacies, or collectively, Customers. These Customers subsequently…View ↗
The Company recognizes revenue from product sales at the point Customers obtain control of the product, which generally occurs upon…View ↗
In accordance with Topic ASC 808, Collaboration Arrangements, Incyte has been identified as the principal in product sales, therefore, we…View ↗
We enter into license agreements for the development and commercialization of our product candidates. License agreements may include…View ↗
-
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗
$172.4M
-
10-K for FY2025, filed Feb 26, 2026
$172.4M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product revenue
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
72% |
Net product revenue, FY2025
$124.8M Sources
|
Sold outright |
|
Collaboration revenue
|
25% |
Collaboration revenue, FY2025
$42.4M Sources
|
|
|
Milestone revenue
|
3.0% |
Milestone revenue, FY2025
$5.1M Sources
|
Who Are Their Customers?
Specialty distributors and specialty pharmacies buy Revuforj directly from Syndax and resell it to pharmacies, hospitals and other customers. Incyte works with Syndax to commercialize Niktimvo.
10-K for FY2025, filed Feb 26, 2026The Company sells Revuforj to specialty distributors and specialty pharmacies, or collectively, Customers. These Customers subsequently…View ↗
The Company has exposure to credit risk in accounts receivable from sales of Revuforj. Revuforj is sold to Specialty Distributors and…View ↗
In late January 2025, we launched Niktimvo for commercial sale in the U.S. in partnership with Incyte and in accordance with the…View ↗
Do Revenues Turn Into Profits?
No. It lost $285.4M in FY2025.
10-K for FY2025, filed Feb 26, 2026
−$273.1MView ↗
10-K for FY2025, filed Feb 26, 2026
−$285.4MView ↗
10-K for FY2025, filed Feb 26, 2026
−$323.2MView ↗
How Are They Changing?
Growing. Revenue grew 23% in 4 years, from $139.7M in FY2021 to $172.4M in FY2025, about 5% a year.
From development to commercial sales
The older report described Syndax as developing revumenib and axatilimab; the latest describes two approved medicines, with Revuforj sold commercially and Niktimvo co-commercialized with Incyte.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026We are a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our two lead product candidates…View ↗
We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved…View ↗
In late November 2024, we launched Revuforj for commercial sale in the United States. In December 2024, revumenib was added to the NCCN…View ↗
In late January 2025, we launched Niktimvo for commercial sale in the U.S. in partnership with Incyte and in accordance with the…View ↗
Loading...
